Arrowstreet Capital
MIRM icon

Arrowstreet Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Arrowstreet Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,885
Closed -$6.27M – 2054
2026
Q1 		$6.27M Sell
67,885
-304,626
-82% -$28.7M ﹤0.01% 1092
2025
Q4 		$29.4M Sell
372,511
-239,807
-39% -$17.2M 0.02% 632
2025
Q3 		$44.9M Buy
612,318
+536,674
+709% +$34.1M 0.03% 490
2025
Q2 		$3.85M Buy
+75,644
New +$3.37M ﹤0.01% 1259
2024
Q1 		– Sell
-17,874
Closed -$528K – 1721
2023
Q4 		$528K Buy
+17,874
New +$541K ﹤0.01% 1212

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's MIRM Position: Q2 2026 in Review

Arrowstreet Capital sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 67,885 shares — an estimated $6.27M sold.

Arrowstreet Capital first reported a position in MIRM in Q4 2023 and held it in 5 quarters. The position peaked at $44.9M in Q3 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Arrowstreet Capital reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 67,885 Mirum Pharmaceuticals shares in Q2 2026, an estimated $6.27M.
  • Arrowstreet Capital first reported a position in Mirum Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Arrowstreet Capital's Mirum Pharmaceuticals position peaked at $44.9M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.